7. Cancer Immunotherapy and Checkpoints

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/26

flashcard set

Earn XP

Description and Tags

Faridi - 643

Last updated 9:36 PM on 5/25/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

27 Terms

1
New cards

List the functions of the immune cells

2
New cards

What are antigen presenting cells (APCs)?

  • Professional v Non-professional

  • Where are MHC II found

  • Where are MHC I found

    • CD4+ v CD8+

3
New cards

After antigens are processed by immature dentritic cells (DCs), what happens?

  • CD4+, CD8+

4
New cards

Using the Kaplam-Meier survival analysis, how can we know if a new therapeutic is an improvement in cancer therapy?

5
New cards

What is the MOA of Rituximab? Which molecule does the agent block?

Know B cell lymphomas over express B cells on cell marker, and want to kill those cells

  • Rituximab therapy "huge game changer" in patient overall time and survival, brought other monoclonal antibodies to light

6
New cards

List the monoclonal antibodies used for cancer immunology

  • Antibody - what is its target and its approved treatment

  • Rituximan targets CD20 and is indicated for non-Hodgkin lymphoma

    • B cell lymphoma

  • Trastuzumab targets HER2/neu and is indicated for breast cancer, gastric or gastroesophageal junction adenocarcinoma

7
New cards

What is antibody dependent cell mediated cytotoxicity (ADCC)

8
New cards

What is antibody dependent cell mediated phagocytosis (ADCP)?

9
New cards

Signaling lymphocytic activation molecule (SLAM) receptor family

What slide is saying:

  • Many of these antibodies, they activate, you know, or they kill the tumor cells in different ways, so they can do it through the cytotoxicity, through the phagocytosis, and then by blocking

  • These pathways.

  • The cell signaling pathways.

10
New cards

Genentech’s T-DM1 Kadcyla (Ado-Trastuzumab Emtansine)

11
New cards

Cancer immunotherapy - Monoclonal Antibodies

  • List the Immune checkpoint inhibitors (ICIs)

    • antibody, its target, and indication

      • Only need to know the ones in red

12
New cards

Immune activation in lymph nodes

  • What two signals are needed for this activation?

13
New cards

B7 cell-surface protein ligands

14
New cards

Negative checkpoints in lymph nodes - prevent overactivation

15
New cards

What is the significance of immune checkpoints (breaks → off)

16
New cards

How do cancer cell utilize checkpoint mechanisms

17
New cards

Immune checkpoint inhibitors

18
New cards

Pembrolizuman (Keytruda)

  • normal immune response

  • tumor evasion and T-cell deactivation

  • T-cell reactivation with KEYTUDA

19
New cards

PD1 (anti-programmed cell death protein 1) inhibitors (3)

  • all bind to PD-1 and inhibits its interaction with its receptors

20
New cards

PDL1 (anti-programmed death ligand 1) inhibitor (3)

21
New cards

What is the significance of CTLA-4 (cytotoxic T-lymphocyte associated antigen 4) - checkpoint inhibitors

  • List the CTLA-4 inhibitors

22
New cards

What is the lymphocyte activation gene 3 (LAG-3)? Which agents blocks LAG-3? What does anti-LAG3 treat?

23
New cards

What are the FDA approved Immune Checkpoint Inhibitors (ICIs)?

  • only need to know the highlighted ones

24
New cards

Know the MOA of treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors (CAR)

25
New cards

Chimeric antigen receptor (CAR) T cell (CAR-T) Therapy

26
New cards

MOA of CAR-T Agent - Kymriah (Tisagenlecleucel)

27
New cards

Aucatzyl